FDA approves Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Matt Turner
Patient Affordability

David Linetsky
Point-of-Care Marketing

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Daniel Sontupe
Market Access

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing